Management of direct oral anticoagulant associated bleeding: Results of a multinational survey.

Y. W. Cheung, S. Barco, B. A. Hutten, J. C. M. Meijers, S. Middeldorp, M. Coppens, In vivo increase in thrombin generation by four-factor prothrombin complex concentrate in apixaban-treated healthy volunteers. Journal of Thrombosis and Haemostasis. ,vol. 13, pp. 1799- 1805 ,(2015) , 10.1111/JTH.13115

M Levi, KT Moore, CF Castillejos, D Kubitza, SD Berkowitz, SZ Goldhaber, M Raghoebar, MR Patel, JI Weitz, JH Levy, None, Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers Journal of Thrombosis and Haemostasis. ,vol. 12, pp. 1428- 1436 ,(2014) , 10.1111/JTH.12599

Deborah M. Siegal, Managing target-specific oral anticoagulant associated bleeding including an update on pharmacological reversal agents. Journal of Thrombosis and Thrombolysis. ,vol. 39, pp. 395- 402 ,(2015) , 10.1007/S11239-015-1167-9

Lisa M. Baumann Kreuziger, Mark T. Reding, Management of Bleeding Associated with Dabigatran and Rivaroxaban: A Survey of Current Practices Thrombosis Research. ,vol. 132, ,(2013) , 10.1016/J.THROMRES.2013.07.011

Stuart J. Connolly, Truman J. Milling, John W. Eikelboom, C. Michael Gibson, John T. Curnutte, Alex Gold, Michele D. Bronson, Genmin Lu, Pamela B. Conley, Peter Verhamme, Jeannot Schmidt, Saskia Middeldorp, Alexander T. Cohen, Jan Beyer-Westendorf, Pierre Albaladejo, Jose Lopez-Sendon, Shelly Goodman, Janet Leeds, Brian L. Wiens, Deborah M. Siegal, Elena Zotova, Brandi Meeks, Juliet Nakamya, W. Ting Lim, Mark Crowther, Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors The New England Journal of Medicine. ,vol. 375, pp. 1131- 1141 ,(2016) , 10.1056/NEJMOA1607887

Bethany T. Samuelson, Adam Cuker, Deborah M. Siegal, Mark Crowther, David A. Garcia, Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants: A Systematic Review Chest. ,vol. 151, pp. 127- 138 ,(2017) , 10.1016/J.CHEST.2016.08.1462

Andrew W. Shih, Mark A. Crowther, Reversal of direct oral anticoagulants: a practical approach Hematology. ,vol. 2016, pp. 612- 619 ,(2016) , 10.1182/ASHEDUCATION-2016.1.612

Sam Schulman, B. Ritchie, S. Nahirniak, P.L. Gross, M. Carrier, A. Majeed, H.-G. Hwang, M. Zondag, Reversal of dabigatran-associated major bleeding with activated prothrombin concentrate: A prospective cohort study Thrombosis Research. ,vol. 152, pp. 44- 48 ,(2017) , 10.1016/J.THROMRES.2017.02.010

Charles V. Pollack, Paul A. Reilly, Joanne van Ryn, John W. Eikelboom, Stephan Glund, Richard A. Bernstein, Robert Dubiel, Menno V. Huisman, Elaine M. Hylek, Chak-Wah Kam, Pieter W. Kamphuisen, Jörg Kreuzer, Jerrold H. Levy, Gordon Royle, Frank W. Sellke, Joachim Stangier, Thorsten Steiner, Peter Verhamme, Bushi Wang, Laura Young, Jeffrey I. Weitz, Idarucizumab for Dabigatran Reversal — Full Cohort Analysis The New England Journal of Medicine. ,vol. 377, pp. 431- 441 ,(2017) , 10.1056/NEJMOA1707278

Ammar Majeed, Anna Ågren, Margareta Holmström, Maria Bruzelius, Roza Chaireti, Jacob Odeberg, Eva-Lotta Hempel, Maria Magnusson, Tony Frisk, Sam Schulman, Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study Blood. ,vol. 130, pp. 1706- 1712 ,(2017) , 10.1182/BLOOD-2017-05-782060